Literature DB >> 26819144

Use of statins and reduced risk of recurrence of VTE in an older population. A population-based cohort study.

Vicky Tagalakis1, Maria Eberg, Susan Kahn, Laurent Azoulay.   

Abstract

We aimed to determine whether statin use is associated with a decreased risk of recurrent venous thromboembolism (VTE) in older patients. We used a pre-assembled cohort of patients at least 65 years of age diagnosed with incident VTE between January 1, 1994 and December 31, 2004 in the province of Québec, Canada and followed until December 31, 2005. Time-dependent Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) and 95 % confidence intervals (CIs) of recurrent VTE associated with current and past use of statins, compared with non-use. The cohort included 25,681 patients with incident VTE. During a mean follow-up of 3.0 years, there were 2343 recurrent VTE events (rate: 3.1 per 100 person-years). Compared with non-use, current use of statins was associated with a decreased risk of VTE recurrence (rates: 1.55 vs 3.47 per 100 per year, respectively; HR: 0.74, 95 % CI: 0.61-0.89), while no association was observed with past use (HR: 0.98, 95 % CI: 0.76-1.25). In a secondary analysis, longer durations of statin use were associated with greater risk reductions (0-6 months, HR 0.82, 95 % CI: 0.67-1.01; 6-12 months, HR 0.62, 95 % CI: 0.43-0.90; ≥ 12 months, HR: 0.50, 95 % CI: 0.33-0.74; p-value for trend ≤ 0.001). The use of statin was associated with a decreased risk of recurrent VTE in older patients. This study supports the need for randomised controlled trials to assess the efficacy and safety of statins in the long-term treatment of VTE.

Entities:  

Keywords:  Deep-vein thrombosis; elderly; pulmonary embolism; statins; venous thromboembolism

Mesh:

Substances:

Year:  2016        PMID: 26819144     DOI: 10.1160/TH15-10-0775

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study.

Authors:  Sherif M El-Refai; Esther P Black; Val R Adams; Jeffery C Talbert; Joshua D Brown
Journal:  Thromb Res       Date:  2017-08-10       Impact factor: 3.944

Review 2.  Statins as a preventative therapy for venous thromboembolism.

Authors:  Alex Wallace; Hassan Albadawi; Peter Hoang; Andrew Fleck; Sailendra Naidu; Grace Knuttinen; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 3.  Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies.

Authors:  Setor K Kunutsor; Samuel Seidu; Kamlesh Khunti
Journal:  Eur Heart J       Date:  2017-05-21       Impact factor: 29.983

4.  Association between cardiovascular risk factors and venous thromboembolism in the elderly.

Authors:  Huijie Wang; Frits R Rosendaal; Mary Cushman; Astrid van Hylckama Vlieg
Journal:  Res Pract Thromb Haemost       Date:  2022-03-01

5.  Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study.

Authors:  Mohammadreza Bordbar; Renée de Mutsert; Melike Cevval; Frits R Rosendaal; J Wouter Jukema; Willem M Lijfering
Journal:  Thromb J       Date:  2021-06-27

6.  Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study.

Authors:  Sigrid K Brækkan; Camila Caram-Deelder; Bob Siegerink; Astrid van Hylckama Vlieg; Saskia le Cessie; Frits R Rosendaal; Suzanne C Cannegieter; Willem M Lijfering
Journal:  Res Pract Thromb Haemost       Date:  2017-05-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.